The Technical Analyst
Trevi Therapeutics Inc [TRVI]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Trevi Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.74% $2.71
America/New_York / 19 apr 2024 @ 15:22
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 186.54 mill |
| EPS: | -0.290 |
| P/E: | -9.33 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 68.96 mill |
| Avg Daily Volume: | 0.306 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.33 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.59x |
| Company: PE -9.33 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.314 (-88.41%) $-2.39 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.45 - 2.98 ( +/- 9.78%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-15 | Galletta Christopher | Buy | 28 500 | Stock Option (right to buy) |
| 2024-02-15 | Simon Farrell | Buy | 175 000 | Stock Option (right to buy) |
| 2024-02-15 | Clark David J | Buy | 175 000 | Stock Option (right to buy) |
| 2024-02-15 | Good Jennifer L | Buy | 630 000 | Stock Option (right to buy) |
| 2024-02-15 | Sciascia Thomas | Buy | 150 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 80.64 |
| Last 98 transactions |
| Buy: 31 017 280 | Sell: 1 379 035 |
Forecast:
16:00 - $2.71
Live Trading Signals (every 1 min)
Forecast
1: 15:31 - $2.71
Forecast 2: 16:00 - $2.71
Forecast 3: 16:00 - $2.71
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.71 (0.74% ) |
| Volume | 0.0758 mill |
| Avg. Vol. | 0.306 mill |
| % of Avg. Vol | 24.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TRVI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Latest Press Releases
2024-04-09 07:30:00 - Press Release
Trevi Therapeutics Announces Abstract Presentation At The American Thoracic Society 2024 International Conference
Professor jacky smith will present on the reduction of cough bouts with nalbuphine er observed in patients with ipf in the canal trial new haven, conn. , april 9, 2024 /prnewswire/ -- trevi therapeutics, inc. (nasdaq: trvi), a clinical-stage biopharmaceutical company developing the investigational therapy haduvio™ (oral nalbuphine er) for the treatment of chronic cough in idiopathic pulmonary fibrosis (ipf) and refractory chronic cough (rcc), today announced that data from the phase 2 canal trial will be presented at the american thoracic society (ats) 2024 international conference being held in san diego, ca, from may 17-22.
2024-04-04 07:30:00 - Press Release
Trevi Therapeutics To Participate In Upcoming April Events
New haven, conn. , april 4, 2024 /prnewswire/ -- trevi therapeutics, inc. (nasdaq: trvi), a clinical-stage biopharmaceutical company developing the investigational therapy haduvio™ (oral nalbuphine er) for the treatment of chronic cough in idiopathic pulmonary fibrosis (ipf) and refractory chronic cough (rcc), today announced that senior management will attend and participate in the following events in april.
2024-04-02 07:30:00 - Press Release
Trevi Therapeutics Adds Clinical Development Expertise In Chronic Cough To Leadership Team
Margaret garin, md, mscr, joins team to advance the development of haduvio in chronic cough indications new haven, conn. , april 2, 2024 /prnewswire/ -- trevi therapeutics, inc. (nasdaq: trvi), a clinical-stage biopharmaceutical company developing the investigational therapy haduvio™ (oral nalbuphine er) for the treatment of chronic cough in idiopathic pulmonary fibrosis (ipf) and refractory chronic cough (rcc), today announced the appointment of margaret garin, md, mscr, as vice president of clinical development.
2024-03-20 16:05:00 - Press Release
Trevi Therapeutics Reports Fourth Quarter And Year End 2023 Financial Results And Provides Business Updates
Reaffirms guidance for the phase 2a river trial of haduvio in rcc patients with topline data expected in the second half of 2024 enrollment progressing in the phase 2b coral dose-ranging trial of haduvio for the treatment of chronic cough in ipf patients human abuse potential study more than 50% enrolled management to host a conference call and webcast today at 4:30 p.m. et new haven, conn.
2024-03-13 16:05:00 - Press Release
Trevi Therapeutics To Report Q4 And Year End 2023 Financial Results And Provide A Corporate Update On March 20, 2024
Conference call and webcast to be held at 4:30 p.m. et new haven, conn.
Latest News
2024-04-18 10:56:08 - Zacks Investment Research
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2024-04-04 09:31:15 - Zacks Investment Research
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-03-20 18:21:10 - Seeking Alpha
Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript
2024-01-17 13:01:26 - Zacks Investment Research
Trevi Therapeutics, Inc. (TRVI) Upgraded to Strong Buy: Here's Why
Trevi Therapeutics, Inc. (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2023-11-30 11:18:14 - Zacks Investment Research
Down -38.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Trevi Therapeutics, Inc. (TRVI)
The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-11-14 11:19:03 - Zacks Investment Research
After Plunging -28.72% in 4 Weeks, Here's Why the Trend Might Reverse for Trevi Therapeutics, Inc. (TRVI)
The heavy selling pressure might have exhausted for Trevi Therapeutics, Inc. (TRVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-11-12 05:46:03 - Seeking Alpha
Trevi Therapeutics, Inc. (TRVI) Q3 2023 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Annabel Samimy - Stifel Rohan Mathur - Oppenheimer Sean Kim - JonesTrading Serge Belanger - Needham & Company Mayank Mamtani - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics Q3 2023 Earnings Conference Call.
2023-10-11 13:32:33 - Zacks Investment Research
Trevi Therapeutics, Inc. (TRVI) Upgraded to Buy: Here's What You Should Know
Trevi Therapeutics, Inc. (TRVI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-08-10 22:49:14 - Seeking Alpha
Trevi Therapeutics, Inc. (TRVI) Q2 2023 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham and Company Leland Gershell - Oppenheimer William Wood - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics' Second Quarter 2023 Earnings Conference Call.
2023-03-16 23:10:04 - Seeking Alpha
Trevi Therapeutics, Inc. (TRVI) Q4 2022 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Jennifer Good - President & Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Leland Gershell - Oppenheimer Nat Charoensook - SVB Securities Sean Kim - Jones Trading Mayank Mamtani - B. Riley Securities Operator Good afternoon and welcome to the Trevi Therapeutics Q4 and Year-End 2022 Earnings Conference Call.